The accelerated approval for patients with HER2 (ERBB2)-mutated disease follows an approval last August for use after prior systemic therapy.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/zongertinib-picks-first-line-metastatic-nsclc-indication-2026a100066z?src=rss
Author :
Publish date : 2026-02-27 10:13:00
Copyright for syndicated content belongs to the linked Source.